The drug-target residence time model: A 10-year retrospective

Nature Reviews Drug Discovery

Volumn 15, Issue 2, 2016, Pages 87-95

  Copeland, Robert A ^a  

^a EPIZYME INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FINASTERIDE; HEAT SHOCK PROTEIN 90; PROTEIN ARGININE METHYLTRANSFERASE; SAQUINAVIR; MACROMOLECULE; PROTEIN BINDING;

BINDING AFFINITY; DRUG BINDING; DRUG BINDING SITE; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IC50; IN VITRO STUDY; ISOMERIZATION; LIGAND BINDING; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; VIRUS RESISTANCE; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; MACROMOLECULE; METABOLISM; PHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY; TIME FACTOR; TRENDS;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; MACROMOLECULAR SUBSTANCES; PROTEIN BINDING; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84957845231     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2015.18     Document Type: Review

References (54)

1. Copeland, R. A., Pompliano, D. L., & Meek, T. D. Drug-Target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5, 730-739 (2006
2. Tummino, P. J., & Copeland, R. A. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47, 5481-5492 (2008
3. Copeland, R. A. The dynamics of drug-Target interactions: drug-Target residence time and its impact on efficacy and safety. Expert Opin. Drug Discov. 5, 305-310 (2010
4. Copeland, R. A. Conformational adaptation in drug-Target interactions and residence time. Future Med. Chem. 3, 1491-1501 (2011
5. Copeland, R. A. Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists (Wiley, 2013
6. Schiele, F., Ayaz, P., & Fernandez-Montalvan, A. A universal homogeneous assay for high-Throughput determination of binding kinetics. Anal. Biochem. 468, 42-49 (2014
7. Zhang, R., & Windsor, W. T. in Antiviral Methods and Protocols, Methods in Molecular Biology (ed. Gong, E. Y.) 59-79 (2013
8. Copeland R. A., et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc. Natl Acad. Sci. USA 91, 11202-11206 (1994
9. Bull, H. G., et al. Mechanism-based inhibition of human steroid 5α reductase by finasteride: enzyme catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor. J. Am. Chem. Soc. USA 118, 2359-2365 (1996
10. Gooljarsingh, L. T., et al. A biochemical rationale for the anticancer effects of HSP90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc. Natl Acad. Sci. USA 103, 7625-7630 (2006
11. Morrison, J. F., & Walsh, C. T. The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Areas Mol. Biol. 61, 201-299 (1988
12. Danielson, U. H. Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process. Future Med. Chem. 1, 1399-1414 (2009
13. Dahl, G., & Akerud, T. Pharmacokinetics and the drug-Target residence time concept. Drug Discov. Today 18, 697-707 (2013
14. Zhang, R., & Monsma, F. The importance of drug-Target residence time. Curr. Opin. Drug Discov. 12, 488-496 (2009
15. Lu, H., & Tonge, P. J. Drug-Target residence time: critical information for lead optimization. Curr. Opin. Chem. Biol. 14, 467-474 (2010
16. Hyre D. E., et al. Cooperative hydrogen bond interactions in the streptavidin-biotin system. Protein Sci. 15, 459-467 (2006
17. Maschera B., et al. Human immunodeficiency virus: mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J. Biol. Chem. 271, 33231-33235 (1996
18. Basavapathruni, A., et al. Conformational adaption drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem. Biol. Drug Des. 80, 971-980 (2012
19. Schneider, E. V., Bottcher, J., Huber, R., Maskos, K., & Neumann, L. Structure-kinetic relationship study of CDK8/CycC specific compounds. Proc. Natl Acad. Sci. USA 110, 8081-8086 (2013
20. Zhang, R. Which trails are your drugs taking? Nat. Chem. Biol. 11, 382-383 (2015
21. Markgren P. O., et al. Relationships between structure and interaction kinetics for HIV-protease inhibitors. J. Med. Chem. 45, 5430-5439 (2002
22. Vauquelin, G. Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time. Expert Opin. Drug Discov. 5, 927-941 (2010
23. Vauquelin, G., & Charlton, S. J. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br. J. Pharmacol. 161, 488-508 (2010
24. Li H. J., et al. A structural and energetic model for the slow-onset inhibition of the Mycobacterium tuberculosis enoyl-CP reductase InhA. ACS Chem. Biol. 9, 986-993 (2014
25. Lai C. T., et al. Rational modulation of the induced-fit conformational change for slow-onset inhibition of Mycobacterium tuberculosis InhA. Biochemistry 54, 4683-4691 (2015
26. Tiwary, P., Limongelli, V., Salvalaglio, M., & Parrinello, M. Kinetics of protein-ligand unbinding: predicting pathways, rates and rate-limiting steps. Proc. Natl Acad. Sci. USA 112, E386-E391 (2009
27. Cusack K. P., et al. Design strategies to address kinetics of drug binding and residence time. Bioorg. Med. Chem. Lett. 25, 2019-2027 (2015
28. Van Aller G., et al. Long residence time inhibition of EZH2 in activated polycomb repressive complex 2. ACS Chem. Biol. 9, 622-629 (2014
29. Chan-Penebre E., et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat. Chem. Biol. 11, 432-437 (2015
30. Lu H., et al. Slow-onset inhibition of the FabI enoyl reductase from Francisella tularensis: residence time and in vivo activity. ACS Chem. Biol. 4, 221-231 (2009
31. Guo, D., Mulder-Krieger, T., Ijzerman, A. P., & Heitman, L. H. Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time. Br. J. Pharmacol. 166, 1846-1859 (2012
32. Sullivan, S. M., & Holyoak, T. Enzymes with lid-gated active sites must operate by an induced fit mechanism instead of conformational selection. Proc. Natl Acad. Sci. USA 105, 13829-13834 (2008
33. Garvey, E. P., et al. Potent inhibitors of HIV 1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T661/M1541 mutant. Biochemistry 48, 1644-1653 (2009
34. González B., et al. The crystal structure of tetrameric methionine adenosyltransferase from rat liver reveals the methionine-binding site. J. Mol. Biol. 300, 363-375 (2000
35. Pearce, F. G., & Andrews, T. J. The relationship between side reactions and slow inhibition of ribulose-bisphosphate carboxylase revealed by a loop 6 mutant of the tobacco enzyme. J. Biol. Chem. 278, 32526-32536 (2003
36. Liu Y., et al. Hepatitis C NS3 protease inhibition by peptidyl-α ketoamide inhibitors: kinetic mechanism and structure. Arch. Biochem. Biophys. 421, 207-216 (2004
37. Kapoor M., et al. Kinetic and structural analysis of the increased affinity of enoyl-CP (acyl-carrier protein) reductase for triclosan in the presence of NAD. Biochem. J. 381, 725-733 (2004
38. Carroll M. J., et al. Evidence for dynamics in proteins as a mechanism for ligand dissociation. Nat. Chem. Biol. 8, 246-252 (2012
39. Luckner, S. R., et al. A slow, tight binding inhibitor of InhA, the enoyl-cyl carrier protein reductase from Mycobacterium tuberculosis. J. Biol. Chem. 285, 14330-14337 (2010
40. Cowan-Jacob, S. W., Mobitz, H., & Fabbro, D. Structural biology contributions to tyrosine kinase drug discovery. Curr. Opin. Cell Biol. 21, 280-287 (2009
41. Luong C., et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase 2. Nat. Struct. Biol. 3, 927-933 (1996
42. Schmidtke, P., Luque, F. J., Murray, J. B., & Barril, X. Shielded hydrogen bonds as structural determinants of binding kinetics: application in drug design. J. Am. Chem. Soc. 133, 18903-18910 (2011
43. Bradshaw J. M., et al. Prolonged and tunable residence time using reversible covalent kinase inhibitors. Nat. Chem. Biol. 11, 525-531 (2015
44. Walkup G. K., et al. Translating slow-binding inhibition kinetics into cellular and in vivo effects. Nat.Chem. Biol. 11, 416-423 (2015
45. Billheimer J. T., et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 99, 3540-3546 (2002
46. Seiffert D., et al. Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia. Blood 101, 58-63 (2003
47. Norman, A. W., Mizwicki, M. T., & Norman, D. P. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat. Rev. Drug Discov. 3, 27-41 (2004
48. Kapur, S., & Seeman, P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J. Psychiatry Neurosci. 25, 161-166 (2000
49. Vauquelin, G., Bostoen, S., Vanderheyden, P., & Seeman, P. Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch. Pharmacol. 385, 337-372 (2012
50. Swinney, D. C. Biochemical mechanisms of drug action: what does it take for success? Nat. Rev. Drug Discov. 3, 801-808 (2004
51. Swinney, D. C. Molecular mechanism of action (MMoA) in drug discovery. Annu. Reports Med. Chem. 46, 301-317 (2011
52. Keseru, G. M., & Swinney, D. C. Thermodynamics and Kinetics of Drug Binding (Wiley-VCH, 2015
53. Ploeger, B. A., van der Graaf, P. H., & Danhof, M. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK PD) modeling. Drug Metab. Pharmacokinet. 29, 84-93 (2009
54. Tillotson B., et al. Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo. J. Biol. Chem. 285, 39835-39843 (2010